Baird Initiates Coverage On Sage Therapeutics with Neutral Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on Sage Therapeutics (NASDAQ:SAGE) with a Neutral rating and a price target of $15.
May 29, 2024 | 9:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Joel Beatty has initiated coverage on Sage Therapeutics with a Neutral rating and a price target of $15.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. The price target of $15 provides a specific valuation benchmark for investors.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100